Insulin Glargine — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

6 Completed trials

5 Sponsors

12 Countries

Phase III

Phase IV

Phase III: 6 Phase IV: 4

Indications tested

Insulin-requiring type 2 diabetes mellitus 1

Sponsors using this IMP

Novo Nordisk A/S 6 Eli Lilly & Co. 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Universita Cattolica Del Sacro Cuore 1 University Medical Center Utrecht 1

All trials

10 total

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 D… Pending

2024-520068-32-00 Phase IV 2 countries Novo Nordisk A/S
SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting

2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Recruiting

2024-519945-31-00 Phase III 4 countries Novo Nordisk A/S
Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment Recruiting

2024-516542-19-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended

2022-502679-43-00 Phase III 1 country Novo Nordisk A/S
A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended

2023-506084-34-00 Phase III 4 countries Novo Nordisk A/S
A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended

2022-502484-38-00 Phase III 3 countries Novo Nordisk A/S
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended

2022-500449-26-00 Phase IV 5 countries University Medical Center Utrecht
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Phase III 8 countries Eli Lilly & Co.
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended

2024-510612-75-00 Phase III 7 countries Novo Nordisk A/S

Showing 1–10 of 10 trials

← All drugs A–Z